Suppr超能文献

醛缩酶B(ALDOB)是透明细胞肾细胞癌的一种预后生物标志物和潜在的免疫治疗靶点。

ALDOB is a prognostic biomarker and a potential immunotherapy target for clear cell renal cell carcinoma.

作者信息

Xu Wu, Wu Dali, Li Cuilian, Yan Lingfei, Peng Bo, Luo Yang, Liu Dawei, Li Qing, Wang Tao

机构信息

Department of Urology, The Fifth Affiliated Hospital, Southern Medical University, Guanzhou, China.

出版信息

PeerJ. 2025 Aug 18;13:e19869. doi: 10.7717/peerj.19869. eCollection 2025.

Abstract

BACKGROUND

Aldolase B (), functioning as a glycolytic enzyme, exhibits a controversial role in malignancies and demonstrates dual potential as both a tumor suppressor and cancer-promoting enzyme. Nevertheless, it is still uncertain if there is a relationship between levels, prognosis, and tumor-infiltrating lymphocytes in clear cell renal cell carcinoma (ccRCC).

OBJECTIVE

This study aims to investigate the prognostic significance of in ccRCC and its potential association with clinicopathological features and tumor immune microenvironment. By integrating multi-database bioinformatics analysis and experimental validation, we seek to elucidate the role of in ccRCC progression and its potential as a predictive biomarker.

METHODS

To ascertain the potential link between level, clinical parameters, and overall survival (OS) in individuals with ccRCC, we employed diverse databases, which include The Cancer Genome Atlas (TCGA), Gene Expression Omnibus (GEO), the Human Protein Atlas (HPA) and The University of Alabama at Birmingham Cancer data analysis Portal (UALCAN). Furthermore, an in-depth analysis of the link between tumor-infiltrating immune cells (TIIC) and was carried out using the TIMER database. Immunohistochemistry (IHC) was applied to identify the level in a tissue microarray.

RESULTS

The expression of demonstrated a strong association with pathologic T stage, pathologic N stage, pathologic M stage, histologic grade, and gender. Decreased level was linked to unfavorable disease-specific survival (DSS), progress free interval (PFI), and OS outcomes ( < 0.001). Subsequently, a marked link was observed between level and a heightened presence of infiltrating Treg, Th17 cells, and neutrophils in ccRCC. IHC showed that the level in ccRCC samples was notably diminished relative to that in the adjacent normal tissues.

CONCLUSIONS

As a prospective predictive indicator for individuals with ccRCC, reduced level exhibited strong correlations with clinical characteristics, unfavorable outcomes, and immune infiltration in individuals with ccRCC.

摘要

背景

醛缩酶B()作为一种糖酵解酶,在恶性肿瘤中发挥着有争议的作用,具有作为肿瘤抑制因子和促癌酶的双重潜力。然而,在透明细胞肾细胞癌(ccRCC)中,醛缩酶B水平、预后与肿瘤浸润淋巴细胞之间是否存在关联仍不确定。

目的

本研究旨在探讨醛缩酶B在ccRCC中的预后意义及其与临床病理特征和肿瘤免疫微环境的潜在关联。通过整合多数据库生物信息学分析和实验验证,我们试图阐明醛缩酶B在ccRCC进展中的作用及其作为预测生物标志物的潜力。

方法

为了确定ccRCC患者醛缩酶B水平、临床参数与总生存期(OS)之间的潜在联系,我们使用了多个数据库,包括癌症基因组图谱(TCGA)、基因表达综合数据库(GEO)、人类蛋白质图谱(HPA)和阿拉巴马大学伯明翰分校癌症数据分析门户(UALCAN)。此外,使用TIMER数据库对肿瘤浸润免疫细胞(TIIC)与醛缩酶B之间的联系进行了深入分析。应用免疫组织化学(IHC)方法在组织芯片中鉴定醛缩酶B水平。

结果

醛缩酶B的表达与病理T分期、病理N分期、病理M分期、组织学分级和性别密切相关。醛缩酶B水平降低与不良的疾病特异性生存期(DSS)、无进展生存期(PFI)和OS结果相关(< 0.001)。随后,观察到醛缩酶B水平与ccRCC中浸润性调节性T细胞、辅助性T细胞17和中性粒细胞数量增加之间存在显著联系。免疫组织化学显示,ccRCC样本中的醛缩酶B水平相对于相邻正常组织明显降低。

结论

作为ccRCC患者的一种前瞻性预测指标,醛缩酶B水平降低与ccRCC患者的临床特征、不良预后和免疫浸润密切相关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b46a/12369605/040ec4729ebd/peerj-13-19869-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验